Kura Oncology (NASDAQ:KURA) Stock Crosses Below 200-Day Moving Average - Should You Sell?

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $6.97 and traded as low as $5.85. Kura Oncology shares last traded at $6.16, with a volume of 1,985,284 shares trading hands.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Mizuho dropped their price target on shares of Kura Oncology from $32.00 to $30.00 and set an "outperform" rating on the stock in a research report on Monday, May 19th. Wedbush reissued an "outperform" rating and set a $36.00 target price on shares of Kura Oncology in a research report on Friday, June 20th. JMP Securities reissued a "market outperform" rating and set a $28.00 target price on shares of Kura Oncology in a research report on Wednesday, June 4th. HC Wainwright reissued a "buy" rating and set a $40.00 target price on shares of Kura Oncology in a research report on Monday, April 28th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Kura Oncology in a research report on Thursday, June 26th. Four investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Kura Oncology presently has a consensus rating of "Moderate Buy" and an average price target of $24.50.

Kura Oncology Stock Performance

The company's 50 day moving average price is $6.08 and its 200-day moving average price is $6.97. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.07 and a current ratio of 8.07. The company has a market cap of $533.27 million, a PE ratio of -2.93 and a beta of 0.40.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The firm had revenue of $14.11 million for the quarter, compared to the consensus estimate of $39.08 million. Equities research analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of KURA. BVF Inc. IL grew its stake in Kura Oncology by 202.0% in the 1st quarter. BVF Inc. IL now owns 7,754,129 shares of the company's stock valued at $51,177,000 after buying an additional 5,186,660 shares in the last quarter. RA Capital Management L.P. purchased a new position in shares of Kura Oncology during the 4th quarter valued at $38,769,000. Millennium Management LLC grew its position in shares of Kura Oncology by 180.1% during the 4th quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock valued at $20,618,000 after purchasing an additional 1,521,954 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Kura Oncology during the 4th quarter valued at $8,518,000. Finally, Marshall Wace LLP purchased a new position in shares of Kura Oncology during the 4th quarter valued at $8,265,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.